Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation. 1993

J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
Département d'Anesthésie-Réanimation, Hôpital Pitie-Salpetriere, Paris, France.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000961 Antilymphocyte Serum Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION. ATGAM,Antilymphoblast Globulins,Antilymphocyte Antibodies,Antilymphocyte Globulin,Lymphocytotoxic Antibodies,Anti-Thymocyte Globulin,Antilymphocyte Immunoglobulin,Antithymocyte Globulin,Antithymoglobulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin,Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine),Pressimmune,Anti Thymocyte Globulin,Anti-Thymocyte Globulins,Antibodies, Antilymphocyte,Antibodies, Lymphocytotoxic,Antibody, Antilymphocyte,Antibody, Lymphocytotoxic,Antilymphoblast Globulin,Antilymphocyte Antibody,Antilymphocyte Globulins,Antilymphocyte Immunoglobulins,Antilymphocyte Serums,Antithymocyte Globulins,Antithymoglobulins,Globulin, Anti-Thymocyte,Globulin, Antilymphoblast,Globulin, Antilymphocyte,Globulin, Antithymocyte,Globulins, Anti-Thymocyte,Globulins, Antilymphoblast,Globulins, Antilymphocyte,Globulins, Antithymocyte,Immunoglobulin, Antilymphocyte,Immunoglobulins, Antilymphocyte,Lymphocyte Immune Globulin, Anti Thymocyte Globulin,Lymphocytotoxic Antibody,Serum, Antilymphocyte,Serums, Antilymphocyte
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine

Related Publications

J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
October 1987, Transplantation proceedings,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
November 1984, Casopis lekaru ceskych,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
November 1969, British medical journal,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
January 1977, Scandinavian journal of urology and nephrology. Supplementum,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
January 1976, Postgraduate medical journal,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
March 1975, Klinicheskaia meditsina,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
December 1974, Ceskoslovenska farmacie,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
January 2005, Transplantation proceedings,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
December 1972, Transplantation proceedings,
J Luciani, and H Benalia, and M O Bitker, and C Mouquet, and E Chartier-Kastler, and S Ourhama, and C Jacobs, and C Chatelain, and P Viars
April 1972, Fortschritte der Medizin,
Copied contents to your clipboard!